I know the headline sounds like bad clickbait, but there is an obesity drug out there that is upsetting the industry. According to a recent New York Times article, the drug is so effective that obese patients who take it can prevent other complications such as diabetes. The drug is Semaglutide from Novo Nordisk and is already marketed for the treatment of type 2 diabetes.
In a clinical study, subjects who injected it weekly for 68 weeks lost nearly 15% of their body weight, compared with just 2.4% in the placebo group. Over a third of the patients who received semaglutide lost more than 20% of their body weight, and many patients had improved symptoms of diabetes and pre-diabetes. Dr. Robert F. Kushner, an obesity researcher at Northwestern University’s Feinberg School of Medicine who led the study, said, “The drug is changing the game. This is the beginning of a new era of effective obesity treatments. “